Experimental therapies for glaucoma
Article Sidebar
Published:
Dec 31, 2014
Keywords:
galucoma, trabecular meshwork, genetic therapy, regenerative medicine, drug delivery systems
Main Article Content
Abstract
In a review on the basis of the present pathogenesis concept of glaucomatous optic neuropathy six elements of glaucoma future treatment strategy: baroprotection, vasoprotection, neuroprotection, gene therapy, regenerative medicine and immunotherapy, were described. Elements of pharmacogenomics in glaucoma and new drug delivery systems were also presented.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Wierzbowska J. Experimental therapies for glaucoma. Ophthatherapy [Internet]. 2014Dec.31 [cited 2024Nov.22];1(4):239-45. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/695
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Varma R, Lee PP, Goldberg I et al. An assessment of the health and economic burden of glaucoma. Am J Ophthalmol. 2011; 152: 515-22.
2. Gupta N, Ang LC, Noël de Tilly L et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol. 2006; 90: 674-8.
3. Rao PV, Deng PF, Sasaki Y et al. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility. Exp Eye Res. 2005; 80: 197-206.
4. Tian B, Kaufman PL. Effect of the Rho-kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res. 2005; 80: 215-25.
5. Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest. Ophthalmol Vis Sci. 2006; 47: 1991-8.
6. Zhang M, Rao PV. Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci. 2005; 46: 4130-8.
7. Njie YF, Kumar A, Qiao Z et al. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest. Ophthalmol Vis Sci. 2006; 47: 1999-2005.
8. Villarreal G Jr, Chatterjee A, Oh SS et al. Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2014; 55: 1657-65.
9. Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. Invest Ophthalmol Vis Sci. 2013; 54: 968-73.
10. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014; 144: 41-9.
11. Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care. 2008; 14: S11-4.
12. Salt TE, Nizari S, Cordeiro MF et al. Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma. Neurotox Res. 2014; 26: 440-6.
13. Kee C, Sohn S, Hwang JM. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci. 2001; 42: 2856-60.
14. Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Brain Res Bull. 2004; 62: 473.
15. Hudde T, Apitz J, Bordes-Alonso R et al. Gene transfer to trabecular meshwork endothelium via direct injection into Schlemm’s canal and in vivo toxicity study. Curr Eye Res. 2005; 30: 1051-9.
16. Angella GJ, Sherwood MB, Balasubramanian L et al. Enhanced short-term plasmid transfection of filtration surgery tissues. Invest Ophthalmol Vis Sci. 2000; 41: 4158-62.
17. Ulmer M, Li J, Yaspan BL et al. Genome-wide analysis of central corneal thickness in primary open-angle glaucoma cases in the NEIGHBOR and GLAUGEN consortia. Invest Ophthalmol Vis Sci. 2012; 53: 4468-74.
18. Chen LJ, Tam PO, Leung DY et al. SNP rs1533428 at 2p16.3 as a marker for late-onset primary open-angle glaucoma. Mol Vis. 2012; 18: 1629-39.
19. Nguyen CT, Vingrys AJ, Bui BV. Dietary ω-3 deficiency and IOP insult are additive risk factors for ganglion cell dysfunction. J Glaucoma. 2013; 22: 269-77.
20. Bull ND, Limb GA, Martin KR. Human Müller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci. 2008; 49: 3449-56.
21. Bull ND, Irvine KA, Franklin RJ et al. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci. 2009; 50: 4244-53.
22. Jiang C, Moore MJ, Zhang X et al. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007; 13: 1783-92.
23. Ellis-Behnke RG, Liang YX, You SW et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA. 2006; 103: 5054-9.
24. Bulte JW, Douglas T, Witwer B et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 2001; 19: 1141-7.
25. Kashiwagi K, Ito K, Haniuda H et al. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci. 2013; 54: 5629-37.
2. Gupta N, Ang LC, Noël de Tilly L et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol. 2006; 90: 674-8.
3. Rao PV, Deng PF, Sasaki Y et al. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility. Exp Eye Res. 2005; 80: 197-206.
4. Tian B, Kaufman PL. Effect of the Rho-kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res. 2005; 80: 215-25.
5. Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest. Ophthalmol Vis Sci. 2006; 47: 1991-8.
6. Zhang M, Rao PV. Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci. 2005; 46: 4130-8.
7. Njie YF, Kumar A, Qiao Z et al. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest. Ophthalmol Vis Sci. 2006; 47: 1999-2005.
8. Villarreal G Jr, Chatterjee A, Oh SS et al. Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2014; 55: 1657-65.
9. Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. Invest Ophthalmol Vis Sci. 2013; 54: 968-73.
10. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014; 144: 41-9.
11. Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care. 2008; 14: S11-4.
12. Salt TE, Nizari S, Cordeiro MF et al. Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma. Neurotox Res. 2014; 26: 440-6.
13. Kee C, Sohn S, Hwang JM. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci. 2001; 42: 2856-60.
14. Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Brain Res Bull. 2004; 62: 473.
15. Hudde T, Apitz J, Bordes-Alonso R et al. Gene transfer to trabecular meshwork endothelium via direct injection into Schlemm’s canal and in vivo toxicity study. Curr Eye Res. 2005; 30: 1051-9.
16. Angella GJ, Sherwood MB, Balasubramanian L et al. Enhanced short-term plasmid transfection of filtration surgery tissues. Invest Ophthalmol Vis Sci. 2000; 41: 4158-62.
17. Ulmer M, Li J, Yaspan BL et al. Genome-wide analysis of central corneal thickness in primary open-angle glaucoma cases in the NEIGHBOR and GLAUGEN consortia. Invest Ophthalmol Vis Sci. 2012; 53: 4468-74.
18. Chen LJ, Tam PO, Leung DY et al. SNP rs1533428 at 2p16.3 as a marker for late-onset primary open-angle glaucoma. Mol Vis. 2012; 18: 1629-39.
19. Nguyen CT, Vingrys AJ, Bui BV. Dietary ω-3 deficiency and IOP insult are additive risk factors for ganglion cell dysfunction. J Glaucoma. 2013; 22: 269-77.
20. Bull ND, Limb GA, Martin KR. Human Müller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci. 2008; 49: 3449-56.
21. Bull ND, Irvine KA, Franklin RJ et al. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci. 2009; 50: 4244-53.
22. Jiang C, Moore MJ, Zhang X et al. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007; 13: 1783-92.
23. Ellis-Behnke RG, Liang YX, You SW et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA. 2006; 103: 5054-9.
24. Bulte JW, Douglas T, Witwer B et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 2001; 19: 1141-7.
25. Kashiwagi K, Ito K, Haniuda H et al. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci. 2013; 54: 5629-37.